Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
Collegium Pharmaceutical (Nasdaq: COLL) has scheduled its fourth quarter and full-year 2024 financial results announcement for Thursday, February 27, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. Investors can access the call via U.S. dial-in (877) 407-8037 or International dial-in (201) 689-8037. An audio webcast will be available on the company's website investor section and will remain accessible for replay approximately two hours after the event.
Collegium Pharmaceutical (Nasdaq: COLL) ha programmato l'annuncio dei suoi risultati finanziari del quarto trimestre e dell'anno intero 2024 per giovedì 27 febbraio 2025, dopo la chiusura del mercato. L'azienda organizzerà una conferenza telefonica e un webcast alle 16:30 ET dello stesso giorno per discutere i risultati. Gli investitori possono accedere alla chiamata tramite il numero U.S. (877) 407-8037 o il numero internazionale (201) 689-8037. Un webcast audio sarà disponibile nella sezione investitori del sito web dell'azienda e rimarrà accessibile per la riproduzione circa due ore dopo l'evento.
Collegium Pharmaceutical (Nasdaq: COLL) ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el jueves 27 de febrero de 2025, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica y un webcast a las 4:30 p.m. ET el mismo día para discutir los resultados. Los inversores pueden acceder a la llamada a través del número U.S. (877) 407-8037 o del número internacional (201) 689-8037. Un webcast de audio estará disponible en la sección de inversores del sitio web de la empresa y permanecerá accesible para su reproducción aproximadamente dos horas después del evento.
콜레기움 제약 (Nasdaq: COLL)는 2024년 4분기 및 연간 재무 결과 발표를 2025년 2월 27일 목요일, 시장 종료 후로 예정했습니다. 회사는 같은 날 오후 4시 30분 ET에 결과를 논의하기 위한 전화 회의와 웹캐스트를 개최할 것입니다. 투자자들은 미국 전화번호 (877) 407-8037 또는 국제 전화번호 (201) 689-8037을 통해 전화 회의에 접속할 수 있습니다. 오디오 웹캐스트는 회사 웹사이트의 투자자 섹션에서 제공되며 이벤트 후 약 2시간 동안 재생할 수 있습니다.
Collegium Pharmaceutical (Nasdaq: COLL) a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le jeudi 27 février 2025, après la clôture du marché. L'entreprise organisera une conférence téléphonique et un webinaire à 16h30 ET le même jour pour discuter des résultats. Les investisseurs peuvent accéder à l'appel via le numéro U.S. (877) 407-8037 ou le numéro international (201) 689-8037. Un webinaire audio sera disponible dans la section investisseurs du site web de l'entreprise et restera accessible pour rediffusion environ deux heures après l'événement.
Collegium Pharmaceutical (Nasdaq: COLL) hat die Bekanntgabe seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für Donnerstag, den 27. Februar 2025, nach Börsenschluss angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen. Investoren können über die US-Nummer (877) 407-8037 oder die internationale Nummer (201) 689-8037 anrufen. Ein Audio-Webcast wird im Investorenbereich der Unternehmenswebsite verfügbar sein und etwa zwei Stunden nach der Veranstaltung zur Wiederholung bereitstehen.
- None.
- None.
STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.
Conference Call Information
To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 2024 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Investor Contact:
Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com
Media Contact:
Cheryl Wheeler
Head of Corporate Communications
communications@collegiumpharma.com
FAQ
When will Collegium Pharmaceutical (COLL) release Q4 2024 earnings?
What time is Collegium's Q4 2024 earnings call?
How can investors access Collegium's Q4 2024 earnings call?
Will Collegium's Q4 2024 earnings call be available for replay?
